Allogenic fecal microbiota transplantation in patients with nonalcoholic fatty liver disease improves abnormal small intestinal permeability: a randomized control trial L Craven, A Rahman, SN Parvathy, M Beaton, J Silverman, K Qumosani, ... Official journal of the American College of Gastroenterology| ACG 115 (7 …, 2020 | 225 | 2020 |
Remdesivir for the treatment of patients in hospital with COVID-19 in Canada: a randomized controlled trial K Ali, T Azher, M Baqi, A Binnie, S Borgia, FM Carrier, YA Cavayas, ... Cmaj 194 (7), E242-E251, 2022 | 141 | 2022 |
Probiotics and the BSH-related cholesterol lowering mechanism: a Jekyll and Hyde scenario SB Choi, LC Lew, SK Yeo, S Nair Parvathy, MT Liong Critical reviews in biotechnology 35 (3), 392-401, 2015 | 109 | 2015 |
Fecal microbiota transplantation plus anti-PD-1 immunotherapy in advanced melanoma: a phase I trial B Routy, JG Lenehan, WH Miller Jr, R Jamal, M Messaoudene, ... Nature medicine 29 (8), 2121-2132, 2023 | 71 | 2023 |
Extended screening costs associated with selecting donors for fecal microbiota transplantation for treatment of metabolic syndrome-associated diseases LJ Craven, S Nair Parvathy, J Tat-Ko, JP Burton, MS Silverman Open forum infectious diseases 4 (4), ofx243, 2017 | 53 | 2017 |
Breaking down the gut microbiome composition in multiple sclerosis A Budhram, S Parvathy, M Kremenchutzky, M Silverman Multiple Sclerosis Journal 23 (5), 628-636, 2017 | 47 | 2017 |
Fecal microbiota transplantation is safe and tolerable in patients with multiple sclerosis: A pilot randomized controlled trial KF Al, LJ Craven, S Gibbons, SN Parvathy, AC Wing, C Graf, KA Parham, ... Multiple Sclerosis Journal–Experimental, Translational and Clinical 8 (2 …, 2022 | 43 | 2022 |
Treating from the inside out: relevance of fecal microbiota transplantation to counteract gut damage in GVHD and HIV infection J Ouyang, S Isnard, J Lin, B Fombuena, X Peng, S Nair Parvathy, Y Chen, ... Frontiers in Medicine 7, 421, 2020 | 21 | 2020 |
Canadian Treatments for COVID-19 (CATCO); Association of Medical Microbiology and Infectious Disease Canada (AMMI) Clinical Research Network and the Canadian Critical Care … K Ali, T Azher, M Baqi, A Binnie, S Borgia, FM Carrier, YA Cavayas, ... CMAJ 194 (7), E242-E251, 2022 | 15 | 2022 |
Improved MAIT cell functions following fecal microbiota transplantation for metastatic renal cell carcinoma M Ninkov, CL Schmerk, M Moradizadeh, SN Parvathy, R Figueredo, ... Cancer Immunology, Immunotherapy 72 (5), 1247-1260, 2023 | 11 | 2023 |
Fecal microbiota transplantation followed by anti–PD-1 treatment in patients with advanced melanoma. WH Miller, B Routy, R Jamal, DS Ernst, D Logan, K Esfahani, K Belanger, ... Journal of Clinical Oncology 40 (16_suppl), 9533-9533, 2022 | 10 | 2022 |
Haplotype analysis of the polymorphic 17 YSTR markers in Kerala nontribal populations SN Parvathy, A Geetha, C Jagannath Molecular biology reports 39, 7049-7059, 2012 | 10 | 2012 |
P864 Combination of fecal microbiota transplantation from healthy donors with anti-PD1 immunotherapy in treatment-naïve advanced or metastatic melanoma patients S Maleki, J Lenehan, J Burton, M Silverman, SN Parvathy, M El-Hajjar, ... Journal for ImmunoTherapy of Cancer 8 (Suppl 1), 2020 | 9 | 2020 |
Y-short tandem repeat haplotype and paternal lineage of the Ezhava population of Kerala, south India P Seema Nair, A Geetha, C Jagannath Croatian medical journal 52 (3), 344-350, 2011 | 9 | 2011 |
Enhanced donor screening for faecal microbial transplantation during COVID-19 SN Parvathy, JG Lenehan, R Fernandes, SM Poutanen, S Hota, ... Gut 70 (11), 2219-2220, 2021 | 8 | 2021 |
Association of Medical Microbiology and Infectious Disease Canada (AMMI) Clinical Research Network and the Canadian Critical Care Trials Group. Remdesivir for the treatment of … K Ali, T Azher, M Baqi, A Binnie, S Borgia, FM Carrier, YA Cavayas, ... CMAJ 194 (7), E242-E251, 2022 | 5 | 2022 |
Preventing adverse events in patients with renal cell carcinoma treated with doublet immunotherapy using fecal microbiota transplantation (FMT): Initial results from perform a … R Fernandes, SN Parvathy, DS Ernst, M Haeryfar, J Burton, M Silverman, ... Journal of Clinical Oncology 40 (16_suppl), 4553-4553, 2022 | 4 | 2022 |
Combination of fecal microbiota transplantation from healthy donors with anti-PD1 immunotherapy in treatment-naïve advanced or metastatic melanoma patients S Maleki, J Lenehan, J Burton, M Silverman, SN Parvathy, M El-Hajjar, ... JOURNAL FOR IMMUNOTHERAPY OF CANCER 8, A11-A12, 2020 | 3 | 2020 |
614 microbiome modification with fecal microbiota transplant from healthy donors before anti-PD1 therapy reduces primary resistance to immunotherapy in advanced and metastatic … B Routy, J Lenehan, B Daisley, M Messaoudene, K Al, C Richard, ... Journal for ImmunoTherapy of Cancer 10 (Suppl 2), 2022 | 2 | 2022 |
Author Correction: Fecal microbiota transplantation plus anti-PD-1 immunotherapy in advanced melanoma: a phase I trial B Routy, JG Lenehan, WH Miller Jr, R Jamal, M Messaoudene, ... Nature Medicine 30 (2), 604-604, 2024 | 1 | 2024 |